DR info

臨床試験数 : 11 / 薬物数 : 20 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 7

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Antioxidants
   University of Colorado, Denver
      2008   Phase 2   NCT01773278   United States;
Cholesterol
   University of Colorado, Denver
      2008   Phase 2   NCT01773278   United States;
Cholesterol supplementation
   Oregon Health and Science University
      2011   -   NCT01356420   United States;
Cholic Acid
   University of Nebraska
      2021   Phase 1/Phase 2   NCT03720990   United States;
Crystalline cholesterol oil-based suspension
   Boston Children’s Hospital
      1998   Phase 1/Phase 2   NCT00272844   United States;
DHC
   Obstetrics and Gynecology Hospital Affiliated to Fudan University
      2020   Phase 0   ChiCTR2000035477   China;
Egg substitute, without cholesterol
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      2005   Phase 2   NCT00114634   United States;
Egg yolk preparation with cholesterol
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      2005   Phase 2   NCT00114634   United States;
Gold
   Obstetrics and Gynecology Hospital Affiliated to Fudan University
      2020   Phase 0   ChiCTR2000035477   China;
Lactose
   Oregon Health and Science University
      2011   -   NCT01434745   United States;
Lovastatin
   Northwestern University
      2011   Phase 2   NCT01110642   United States;
N-acetyl cysteine
   Johns Hopkins University
      2022   Phase 2   NCT04381897   United States;
OraPlus
   Forbes Porter, M.D.
      2003   Phase 2   NCT00064792   United States;
Simvastatin
   Oregon Health and Science University
      2011   -   NCT01434745   United States;
Simvastatin Susp.
   Forbes Porter, M.D.
      2003   Phase 2   NCT00064792   United States;